544 J.M. Walker and A.G. Hohmann
Adams IB, Compton DR, Martin BR (1998) Assessment of anandamide interaction with
the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autora-
diographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209–
1217
Ahluwalia J, Urban L, Capogna M, Bevan S, Nagy I (2000) Cannabinoid 1 receptors are
expressed in nociceptive primary sensory neurons. Neuroscience 100:685–688
Ahluwalia J, Urban L, Bevan S, Capogna M, Nagy I (2002) Cannabinoid 1 receptors are
expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive
primary sensory neurones. Neuroscience 110:747–753
Akil H, Mayer DJ, Liebeskind JC (1976) Antagonism of stimulation-produced analgesia by
naloxone, a narcotic antagonist. Science 191:961–962
Arner S, Meyerson BA (1988) Lack of analgesic effect of opioids on neuropathic and idio-
pathic forms of pain [see comments]. Pain 33:11–23
Averill S, McMahon SB, Clary DO, Reichardt LF, Priestley JV (1995) Immunocytochemical
localization of trkA receptors in chemically identified subgroups of adult rat sensory
neurons. Eur J Neurosci 7:1484–1494
Baumann TK, Simone DA, Shain CN, LaMotte RH (1991) Neurogenic hyperalgesia: the
search for the primary cutaneous afferent fibers that contribute to capsaicin-induced
pain and hyperalgesia. J Neurophysiol 66:212–227
Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V, Rice AS
(2000) Role of the endogenous cannabinoid system in the formalin test of persistent
pain in the rat. Eur J Pharmacol 396:85–92
Beecher HK (1959) The measurement of subjective responses: quantitative effects of drugs.
Oxford University Press, New York, pp 164–166
Bellgowan PS, Helmstetter FJ (1996) Neural systems for the expression of hypoalgesia during
nonassociative fear. Behav Neurosci 110:727–736
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional
role of high-affinity anandamide transport, as revealed by selective inhibition. Science
277:1094–1097
Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L,
Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid
glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol
353:23–31
BereiterDA,BereiterDF,HirataH(2002)Topicalcannabinoidagonist,WIN55,212-2,reduces
cornea-evoked trigeminal brainstem activity in the rat. Pain 99:547–556
Berkley KJ, Hubscher CH (1995) Are there separate central nervous system pathways for
touch and pain? Nat Med 1:766–773
Besse D, Lombard MC, Zajac JM, Roques BP, Besson JM (1990) Pre- and postsynaptic
distribution ofμ,δandκopioid receptors in the superficial layers of the cervical dorsal
horn of the rat spinal cord. Brain Res 521:15–22
Bicher HI, Mechoulam R (1968) Pharmacological effects of two active constituents of mar-
ihuana. Arch Int Pharmacodyn Ther 172:24–31
Bisogno T, Melck D, Bobrov M, Gretskaya NM, Bezuglov VV, De Petrocellis L, Di Marzo
V (2000) N-Acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and
inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Biochem J 351:817–824
Bloom AS, Dewey WL, Harris LS, Brosius KK (1977) 9-nor-9beta-hydroxyhexahydro-
cannabinol, a cannabinoid with potent antinociceptive activity: comparisons with mor-
phine. J Pharmacol Exp Ther 200:263–270
Breyer RM, Bagdassarian CK, Myers SA, Breyer MD (2001) Prostanoid receptors: subtypes
and signaling. Annu Rev Pharmacol Toxicol 41:661–690
Bridges D, Ahmad K, Rice AS (2001) The synthetic cannabinoid WIN55,212-2 attenuates
hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 133:586–
594